Related Experiment Video
Updated: Aug 19, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Therapy for systemic urothelial cancer recurrence]
1Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg/Saar. jan.lehmann@uniklinikum-saarland.de
Abstract:
Detailed data on treating systemic recurrences of urothelial cancer after radical cystectomy and/or radical upper tract surgery are sparse. This review describes the data available from two large clinical phase III trials, one on systemic chemotherapy for metastatic/inoperable urothelial cancer and the other on adjuvant systemic chemotherapy after radical cystectomy for locally advanced bladder cancer. In addition, an overview of contemporary series on metastasectomy for urothelial cancer with palliative as well as curative intent is presented. The impact of therapeutic options for the treatment of systemic urothelial cancer recurrences such as radiotherapy, surgery or systemic first and second line therapy represented by conventional chemotherapy and contemporary target therapy are discussed.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Kidney Transplant II: Surgical Procedure
Urinary Tract Calculi V: Nursing Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
